Accord BioPharma and EVERSANA Announce Partnership to Support the Launch of CAMCEVI® for the Treatment of Advanced Prostate Cancer in Adults in the U.S.

CHICAGO — June 29, 2022 — EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, and Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., today announced a partnership to support the recent launch of CAMCEVI® (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults. Accord BioPharma is heading distribution in the United States. The U.S. Food and Drug Administration approved the New Drug Application (NDA) for CAMCEVI from Foresee Pharmaceuticals on May 25, 2021.

To view the press release, click here.